BioMarin Pharmaceutical Inc.
BMRNNASDAQHealthcare● Active
$57.31
+$0.76(+1.34%)
Market Cap$11.1B
P/E Ratio—
52W High$66.28
52W Low$49.26
BioMarin Pharmaceutical Inc. (BMRN) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BMRN · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.35B | $0.43B | $0.17B | $0.14B | ($0.06B) |
| Depreciation & Amort. | $0.08B | $0.10B | $0.10B | $0.10B | $0.11B |
| Stock-Based Comp. | $0.18B | $0.20B | $0.21B | $0.20B | $0.20B |
| Change in Working Capital | ($0.11B) | ($0.22B) | ($0.34B) | ($0.10B) | $0.07B |
| Net Cash from Operations | $0.83B | $0.57B | $0.16B | $0.18B | $0.30B |
| Investing Activities | |||||
| Capital Expenditure | ($0.10B) | ($0.10B) | ($0.10B) | ($0.12B) | ($0.12B) |
| Purchases of Investments | ($0.36B) | ($0.41B) | ($0.87B) | ($0.61B) | ($0.94B) |
| Sales of Investments | $0.34B | $0.63B | $0.86B | $0.62B | $0.69B |
| Net Cash from Investing | ($0.41B) | $0.14B | ($0.11B) | ($0.02B) | ($0.37B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.49B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Cash from Financing | ($0.04B) | ($0.53B) | ($0.02B) | ($0.02B) | ($0.00B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.72B | $0.48B | $0.06B | $0.05B | $0.19B |
| FCF Margin %(computed) | 22.51% | 16.66% | 2.59% | 2.62% | 10.04% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more BioMarin Pharmaceutical Inc. data
About BioMarin Pharmaceutical Inc. (BMRN) Cash Flow Statement
BioMarin Pharmaceutical Inc. generated operating cash flow of $0.83B and free cash flow of $0.72B for 2025 — a FCF margin of 22.51%. Capital expenditure was ($0.10B).
Frequently asked questions
BMRN · 4 questionsBioMarin Pharmaceutical Inc. generated free cash flow of $0.72B for 2025, up 52.5% year-over-year.
BMRN free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10